

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
 17719 (PC27263A)

In Re Application Of: Manuela Villa, et al.

OIPS  
MAR 07 2005

PATENT & TRADEMARK OFFICE  
U.S. DEPARTMENT OF COMMERCE

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/522,254	January 25, 2005	Unassigned	23389	Unassigned	Unassigned

**Title: BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM**

Address to:

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
17719 (PC27263A)

In Re Application: Manuela Villa, et al.

MAR 07 2005

PATENT & TRADEMARK OFFICE

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/522,254	January 25, 2005	Unassigned	23389	Unassigned	Unassigned

Title: BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of \_\_\_\_\_ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.

Charge the amount of \_\_\_\_\_

Credit any overpayment.

Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

March 3, 2005


(Date)

Signature of Person Mailing Correspondence

Peter I. Bernstein

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.



Signature

Dated: March 3, 2005

Peter I. Bernstein

Registration No. 43,497

Scully, Scott, Murphy & Presser  
400 Garden City Plaza-Suite 300  
Garden City, New York 11530  
516-742-4343

PIB:dg

CC:



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Manuela Villa, et al.      **Examiner:** Unassigned  
**Serial No.:** 10/522,254      **Art Unit:** Unassigned  
**Filed:** January 25, 2005      **Docket:** 17719 (PC27263A)  
**For:** BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM      **Dated:** March 3, 2005

**Confirmation No.:** Unassigned

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. United States Patent Application Publication No. 2003/0073672 A1, published April 17, 2003 to Breitenbacher et al.;
2. PCT International Publication No. WO 02/064574 A2, published August 22, 2002;
3. PCT International Publication No. WO 02/12242 A2, published February 14, 2002;

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 3, 2005


  
Peter I. Bernstein

4. PCT International Publication No. WO 96/12720, published May 2, 1996;
5. Kikuchi C. et al., "Tetrahydrothienopyridylbutyl-Tetrahydrobenzindoles: New Selective Ligands of the 5-HT<sub>7</sub> Receptor", *Bioorganic & Medicinal Chemistry Letters*, 12(18):2549-2552 (2002), XP-002256018;
6. Singh P. et al., "Quantitative Structure-Activity Relationship Studies on a New Class of Antihypertensive Agents: Derivatives of 3-Aryl-4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-c]Pyridine", *Quantitative Structure-Activity Relationships*, 9(1):29-32 (1990), XP-001155089;
7. Winters G. et al., "Synthesis, in Vitro [<sup>3</sup>H]Prazosin Displacement, and in Vivo Activity of 3-Aryl-4,5,6,7-Tetrahydropyrazolo[4,3-c]Pyridines, a New Class of Antihypertensive Agents", *J. Med. Chem.*, 28(7):934-940 (1985), XP-002256019;
8. Radinov R. et al., "3-Phenylpyrazolo[4,3-c]Pyridine and Derivatives: Structure Determination", *Journal of Molecular Structure*, 158:99-108 (1987), XP-009018257;
9. Lackey K. et al., "The Discovery of Potent cRaf1 Kinase Inhibitors", *Bioorganic & Medicinal Chemistry Letters*, 10(3):223-226 (2000), XP-004188821; and
10. Philip Cohen, "The Development and Therapeutic Potential of Protein Kinase Inhibitors", *Current Opinion in Chemical Biology*, 3(4):459-465 (1999), XP-002216616.

The references were cited in a Search Report dated October 27, 2003 received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(b), no statement or fee is required.

Respectfully submitted,



Peter I. Bernstein  
Registration No. 43,497

Scully, Scott, Murphy & Presser  
400 Garden City Plaza-Suite 300  
Garden City, New York 11530  
(516) 742-4343

PIB:dg

MAR 8 7 2005

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional) 17719 (PC27263A)		Application Number 10/522,254			
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		Applicant(s) Manuela Villa, et al.					
		Filing Date January 25, 2005		Group Art Unit Unassigned			
		<b>U.S. PATENT DOCUMENTS</b>					
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
<b>U.S. PATENT APPLICATION PUBLICATIONS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA	2003/0073672 A1	4/17/03	Breitenbucher et al.			
	AB						
	AC						
<b>FOREIGN PATENT DOCUMENTS</b>							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/064574 A2	8/22/02	PCT				
	WO 02/12242 A2	2/14/02	PCT				
	WO 96/12720	5/2/96	PCT				
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Kikuchi C. et al., "Tetrahydrothienopyridylbutyl-Tetrahydrobenzindoles: New Selective Ligands of the 5-HT, Receptor", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 12(18):2549-2552 (2002), XP-002256018					
		Singh P. et al., "Quantitative Structure-Activity Relationship Studies on a New Class of Antihypertensive Agents: Derivatives of 3-Aryl-4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-c]Pyridine", <i>Quantitative Structure-Activity Relationships</i> , 9(1):29-32 (1990), XP-001155089					
		Winters G. et al., "Synthesis, in Vitro [ <sup>3</sup> H]Prazosin Displacement, and in Vivo Activity of 3-Aryl-4,5,6,7-Tetrahydropyrazolo[4,3-c]Pyridines, a New Class of Antihypertensive Agents", <i>J. Med. Chem.</i> , 28(7):934-940 (1985), XP-002256019					
EXAMINER			DATE CONSIDERED				
<small>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

MAR 07 2005

PATENT &amp; TRADEMARK OFFICE

LIST OF PRIOR ART  
CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. (Optional)

17719 (PC27263A)

Application Number

10/522,254

Applicant(s)

Manuela Villa, et al.

Filing Date

January 25, 2005

Group Art Unit

Unassigned

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Radinov R. et al., "3-Phenylpyrazolo[4,3-c]Pyridine and Derivatives: Structure Determination", <i>Journal of Molecular Structure</i> , 158:99-108 (1987), XP-009018257
	Lackey K. et al., "The Discovery of Potent cRaf1 Kinase Inhibitors", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 10(3):223-226 (2000), XP-004188821
	Philip Cohen, "The Development and Therapeutic Potential of Protein Kinase Inhibitors", <i>Current Opinion in Chemical Biology</i> , 3(4):459-465 (1999), XP-002216616

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.